- Home
- / AC Immune
AC Immune
Stock Price
$3
2024-10-29
Market Capitalization
$297.8 M
2024-10-29
Revenue
CHF14.8 M
FY, 2023
AC Immune Summary
Company Summary
- Overview
- AC Immune is a biopharmaceutical company developing therapeutics against Alzheimer´s disease and other conformational diseases. Its technology platforms allow to discover, design, and develop antibodies, small molecules, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
- Type
- Public
- Status
- Active
- Founded
- 2003
- HQ
- Lausanne, CH | view all locations
- Website
- https://www.acimmune.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Marie Kosco-Vilbois, Chief Scientific Officer
Johannes Streffer, Chief Medical Officer
Christopher Roberts, Interim Chief Financial Officer Vice President, Finance
Operating MetricsView all
Partnered Products
5
Q3, 2022
Products in Development
16
Q3, 2022
AC Immune Financials
Summary Financials
- Revenue (FY, 2023)
- CHF14.8M
- Gross profit (FY, 2023)
- CHF16.3M
- Net income (FY, 2023)
- (CHF54.2M)
- Cash (FY, 2023)
- CHF78.5M
- EBIT (FY, 2023)
- (CHF53.6M)
- Enterprise value
- $222.8M